SkyLimit, The survival capacity of the recGBM patients receiving the Adj ATL-DC + PD-1 mAb is spectacular. OTOH, why is the mOS of the recGBM group receiving the Neoadj PD1 mAb + Adj ATL-DC only 275 days (about 9 months) while the JAMA article reported that the 64 crossover patients who received only DCVax-L (Adj ATL-DC) after their progression, had thereafter an mOS of more than 13 months?
That seems especially strange because the 64 crossover patients received the vaccine prepared from the primary tumor whereas the group receiving on progression, Neoadj PD1 mAb + adj ATL-DC, were treated with the more homologous vaccine which was prepared from the recurrent tumor.
Market Data 
Markets 
AI
